Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASTOR: 177Lu-DOTATATE vs Interferon alpha-2b in GI-NETs
NCT01860742Phase 3Withdrawn
- Sponsor
- Institut Jules Bordet
- Start
- Dec 2014
- Primary completion
- Oct 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lutetium Lu 177 dotatate in gastrointestinal neuroendocrine tumor, sponsored by Institut Jules Bordet. Planned start Dec 2014; status: withdrawn.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
gastrointestinal neuroendocrine tumor
Beyond the preview
Go deeper on NCT01860742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01860742.